- SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa.
- Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024
BioVie Achieved Alignment With The FDA On Its Upcoming SUNRISE-PD Trial In Parkinson's Disease. As A Result, The Company Is Conducting Trial Start-up Activities With A View To Initiate Patient Screening In Q4 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated